Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

NCT05305794 on ClinicalTrials.gov · last registry update 2026-09-29

A small phase 3 — 76 participants, against a typical 424. Due to report August 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Percentage of time spent within glycemic target range (0.70-1.80 g/l). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 12 July 2022 — 4 years so far.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Centre Hospitalier Universitaire Dijon
Sponsor type: Other
Enrollment: 76
Started: 2022-07-12
Primary completion: 2028-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of time spent within glycemic target range (0.70-1.80 g/l)

Conditions studied

Double Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.